Potential role for the nuclear transcription factor NF-κB in the pathogenesis of ureteropelvic junction obstruction

Journal of Endourology

Volumn 16, Issue 8, 2002, Pages 611-615

  Ruiz Deya, Gilberto ^a   Sikka, Suresh C ^a   Thomas, Raju ^a   Abdel Mageed, Asim B ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CELL HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOSCOPIC SURGERY; FEMALE; GENE EXPRESSION; HUMAN; HYDRONEPHROSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PATHOGENESIS; PRIORITY JOURNAL; PYELOPLASTY; PYELOTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; URETEROPELVIC JUNCTION OBSTRUCTION; UROTHELIUM;

EID: 0036807118     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/089277902320913323     Document Type: Article

References (17)

1. Bauer SB. Anomalies of the kidney and ureteropelvic junction. In: Walsh PC, Retik AB, Vaughn ED, Wein AP (eds): Campbell's Urology, Ed 7. Philadelphia: WB Saunders, 1998, pp 1739-1749.
2. Jabbour ME, Goldfischer ER, Anderson AE, Smith AD, Kushner L. Endopyelotomy failure is associated with reduced transforming growth factor-β. J Urol 1998;160:1991-1994.
3. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhanced sequences. Cell 1986;46:705.
4. Baldwin AS Jr. NF-κB and IκB proteins: New discoveries, and insights. Annu Rev Immunol 1996;14:649.
5. DiDonato J, Mercurio F, Rosette C. Mapping of inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 1996;16:1295-1304.
6. Barnes PJ, Kurin M. Nuclear factor kappa B, a pivotal transcription factor I chronic inflammatory disease. N Engl J Med 1997;336: 1066-1071.
7. Park JM, Bloom DA. The pathophysiology of ureteropelvic junction obstruction. Urol Clin North Am 1998;25:281-288.
8. Hanna MK, Jeffs RD, Sturgess JM. Ureteral structure and ultrastructure II: Congenital ureteropelvic junction obstruction and primary megaureter. J Urol 1976; 116:725-730.
9. Dilenz EZ, Liatsikos EN, Smith AD. Ureteral ischemia model: An explanation of ureteral dysfunction after chronic obstruction. J Endourol 2001;15:213-216.
10. Danuser H, Ackermann DK, Bohlen D, Studer UE. Endopyelotomy for primary ureteropelvic junction obstruction: Risk factors determine the success rate. J Urol 1998;159:66.
11. Brennan EM, Maini RN, Feldmann M. Cytokine expression in chronic inflammatory disease. Br Med Bull 1995;51:368-384.
12. Papavassiliou AG. Transcription factors. N Engl J Med 1995;332: 45-47.
13. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription-factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996;39:581-591.
14. Klement JF, Rice NR, Car BD, et al. IκBα deficiency results in a sustained NF-κB response and severe widespread dermatitis in mice. Mol Cell Biol 1996;16:2341-2349.
15. Kopp FB, Ghosh S. NF-κB and rel proteins in innate immunity. Adv Immunol 1995;58:1-27.
16. Jabbour ME, Goldfischer ER, Anderson, Smith AD, Kushner L. Endopyelotomy failure is associated with reduced transforming growth factor beta. J Urol 1998;160:1991-1994.
17. Palmer LS, Maizels M, Kaplan WE, Firkit CF, Cheng EY. Urine levels of transforming growth factor beta 1 in children with ureteropelvic junction obstruction. Urology 1997;50:769-773.